盼星星盼月亮，盼著Keytruda您進中國市場……
·存在EGFR，ALK等敏感突變的患者，考慮優先應用相應的靶向藥物；
·不存在敏感突變，但存在PD-L1表達陽性的患者，優先使用PD-1抑制劑；
化療真的挺受罪，但也別妖魔化，很多癌症還是非常有效的
·病情緩解程度：Keytruda和化療在客觀緩解率（ORR）上不分上下（27.3%對26.5%），但Keytruda的緩解時間長達20.2個月，遠好於化療組的8-10個月；
·分組分析：Keytruda最明顯的優勢區域是PD-L1表達超過50%的患者群體，中位生存期可從12.2個月延長到20個月；對PD-L1表達超過20%和超過1%的患者，Keytruda也可將生存期延長4.6個月
車到山前必有路嘛。奇點糕覺得，今年就將進入中國的PD-1抑制劑們，絕對不會讓人失望的。
1.Gilberto L, Wu Y L, Iveta K, et al. Pembrolizumab versus platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score ≥ 1%: Open-label, phase 3 KEYNOTE-042 study[J]. Journal of Clinical Oncology, 2018, 36, suppl; abstr LBA4.
2.Soria J C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer[J]. New England Journal of Medicine, 2018, 378(2): 113-125.
3.Antonia S J, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer[J]. New England Journal of Medicine, 2017, 377(20): 1919-1929.
4.https://www.nytimes.com/2018/04/16/health/lung-cancer-immunotherapy.html?rref=collection%2Fsectioncollection%2Fhealth
5.Herbst R S, Baas P, Kim D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. The Lancet, 2016, 387(10027): 1540-1550.
6.Reck M, Rodríguez-Abreu D, Robinson A G, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer[J]. New England Journal of Medicine, 2016, 375(19): 1823-1833.
7.https://www.medscape.com/viewarticle/897538
8.https://endpts.com/mercks-keytruda-builds-a-commanding-lead-in-frontline-lung-cancer-with-data-from-two-more-landmark-trials/
奇點：50萬極客醫生熱愛的醫療科技媒體
閱讀更多 奇點網 的文章
